aluminum phosphate has been researched along with Respiratory Syncytial Virus Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ellingsworth, L; Gilbert, BE; Glenn, G; Guebre-Xabier, M; Liu, Y; Lu, H; Patel, N; Piedra, PA; Smith, G | 1 |
| Capellan, J; Guasparini, R; Langley, JM; Li, M; McGeer, A; Meekison, W; Predy, G; Sales, V; Wang, E | 1 |
1 trial(s) available for aluminum phosphate and Respiratory Syncytial Virus Infections
| Article | Year |
|---|---|
A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aluminum Compounds; Antibodies, Viral; Antibody Formation; Dose-Response Relationship, Immunologic; Female; Hemagglutination Inhibition Tests; Humans; Male; Neutralization Tests; Phosphates; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Vaccines; Respiratory Syncytial Viruses; Vaccines, Subunit | 2009 |
1 other study(ies) available for aluminum phosphate and Respiratory Syncytial Virus Infections
| Article | Year |
|---|---|
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Topics: Adjuvants, Immunologic; Aluminum Compounds; Animals; Antibodies, Neutralizing; Antibodies, Viral; Antibody Affinity; Antiviral Agents; Drug Resistance, Viral; Epitopes; Female; Male; Mutation; Nanoparticles; Palivizumab; Phosphates; Rats; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Vaccines; Respiratory Syncytial Virus, Human; Sigmodontinae; Vaccination; Viral Fusion Proteins | 2018 |